Evidence against a rate-limiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and β-cell dysfunction

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 3, 2001, Pages 1235-1239

  Stumvoll, Michael ^a   Fritsche, Andreas ^a   Stefan, Norbert ^a   Hardt, Elke ^a   Häring, Hans ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROINSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HORMONAL REGULATION; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESPONSE; MALE; METABOLIC ACTIVATION; PANCREAS DISEASE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN PROCESSING; SECRETORY GRANULE;

ADULT; ARGININE; BLOOD GLUCOSE; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; INSULIN; ISLETS OF LANGERHANS; KINETICS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROINSULIN; PROTEIN PRECURSORS;

EID: 0035044338     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.3.1235     Document Type: Article

References (13)

1. What β-cell defect could lead to hyperproinsulinemia in NIDDM? Some clues from recent advances made in understanding the proinsulin-processing mechanism
2. Metabolism of endogenous proinsulin and insulin in man
3. Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus
4. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance
5. A sensitive radioimmunoassay for human proinsulin, with sequential use of antisera to C-peptide and insulin
6. Relative hyperproinsulinemia as a sign of islet dysfunction in women with impaired glucose tolerance
7. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM
8. Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance
9. Insulin secretion and insulin sensitivity in people with impaired glucose tolerance
10. Characterisation of β-cell dysfunction of impaired glucose tolerance. Evidence for impairment of incretin-induced insulin secretion
11. Biological effects and metabolic rates of glucagonlike peptide-17-36 amide and glucagonlike peptide-17-37 in healthy subjects are indistinguishable
12. Pancreatic β-cell dysfunction as the primary genetic lesion in NIDDM